Résumé
Objective:To investigate the clinical efficacy of recombinant human interferon α-2b gels combined with ulcer powders for external use in the treatment of cervicitis patients with human papillomavirus infection. Methods: Totally 76 cases of cervicitis patients with human papillomavirus infection were randomly divided into the observation group and the control group. The observation group was treated by recombinant human interferonα-2b gels combined with ulcer powders for external use through vaginal administration, once every 2d on bedtime. The control group was treated only by ulcer powders for external use. After the 6-month treatment, the HPV negative conversion rate, clinical efficacy and adverse drug reactions in the two groups were detected. Results:After the treatment, the HPV negative conversion rate of the observation group was 83. 33%, which was higher than that of the control group (60. 00%, P <0. 001). The total effective rate of the observation group was 88. 89%, which was higher than that of the control group (82. 50%, P < 0. 05). Conclusion: The clinical efficacy of recombinant human interferon α-2b gels combined with ulcer powders for external use in the treatment of cervicitis patients with human papillomavirus infection is significant, which is worthy of wider application.